Neurofibromatosis type 1

Handbook of Clinical Neurology

Volumn 132, Issue , 2015, Pages 75-86

  Anderson, Jacqueline L ^a   Gutmann, David H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Caf au lait macules; Malignant peripheral nerve sheath tumor; Neurofibroma; Optic pathway glioma; Von Recklinghausen

Indexed keywords

BRAIN NEOPLASMS; GENETICS; HUMAN; NEUROFIBROMATOSIS 1; PATHOLOGY; PATHOPHYSIOLOGY; SKIN; SKIN DISEASES;

BRAIN NEOPLASMS; HUMANS; NEUROFIBROMATOSIS 1; SKIN; SKIN DISEASES;

EID: 84961240917     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62702-5.00004-4     Document Type: Chapter

References (141)

1. Avery R.A., Ferner R.E., Listernick R., et al. Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research. J Neurooncol 2012, 110:1-7.
2. Bajenaru M.L., Hernandez M.R., Perry A., et al. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003, 63:8573-8577.
3. Basu T.N., Gutmann D.H., Fletcher J.A., et al. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356:713-715.
4. Bollag G., Clapp D.W., Shih S., et al. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 1996, 12:144-148.
5. Boyd K.P., Korf B.R., Theos A. Neurofibromatosis type 1. J Am Acad Dematol 2009, 61:1-14.
6. Brown J.A., Gianino S.M., Gutmann D.H. Defective cAMP generation underlies the sensitivity of CNS neurons to neurofibromatosis-1 heterozygosity. J Neurosci 2010, 30:5579-5589.
7. Brunetti-Pierri N., Doty S.B., Hicks J., et al. Generalized metabolic bone disease in neurofibromatosis type 1. Mol Genet Metab 2008, 94:105-111.
8. Buchberg A.M., Cleveland L.S., Jenkins N.A., et al. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 1990, 347:291-294.
9. Cairns A.G., North K.N. Cerebrovascular dysplasia in neurofibromatosis type 1. J Neurol Neurosurg Psychiatry 2008, 79:1165-1170.
10. Cichowski K., Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104:593-604.
11. Cichowski K., Shih T.S., Schmitt E., et al. Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286:2172-2176.
12. Costa R.M., Federov N.B., Kogan J.H., et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature 2002, 415:526-530.
13. Crowe F. Axillary freckling as a diagnostic aid in neurofibromatosis. Ann Intern Med 1964, 61:1142-1143.
14. Crowe F., Schull W., Neel J. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis 1956, Charles C Thomas, Springfield, IL.
15. Cui Y., Costa R.M., Murphy G.G., et al. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cell 2008, 135:549-560.
16. Dasgupta B., Dugan L.L., Gutmann D.H. The neurofibromatosis 1 gene product neurofibromin regulates pituitary adenylate cyclase-activating polypeptide-mediated signaling in astrocytes. J Neurosci 2003, 23:8949-8954.
17. Dasgupta B., Li W., Perry A., et al. Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes. Cancer Res 2005, 65:236-245.
18. Dasgupta B., Yi Y., Chen D.Y., et al. Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors. Cancer Res 2005, 65:2755-2760.
19. de Blank P.M., Berman J.I., Liu G.T., et al. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro Oncol 2013, 15:1088-1095.
20. De Luca A., Schirinzi A., Buccino A., et al. Novel and recurrent mutations in the NF1 gene in Italian patients with neurofibromatosis type 1. Hum Mutat 2004, 23:629.
21. DeBella K., Szudek J., Friedman J.M. Use of the National Institutes of Health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000, 105:608-614.
22. DeClue J.E., Papageorge A.G., Fletcher J.A., et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69:265-273.
23. Derlin T., Tornquist K., Münster S., et al. Comparative effectiveness of 18 F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med 2013, 38:e19-e25.
24. Dilts C.V., Carey J.C., Kircher J.C., et al. Children and adolescents with neurofibromatosis 1: a behavioral phenotype. J Dev Behav Pediatr 1996, 17:229-239.
25. DiPaolo D.P., Zimmerman R.A., Rorke L.B., et al. Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain. Radioloy 1995, 195:721-724.
26. Ducatman B.S., Scheithauer B.W., Piepgras D.G., et al. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57:2006-2021.
27. Dulai S., Briody J., Schindeler A., et al. Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 2007, 27:472-475.
28. El Khassawna T., Toben D., Kolanczyk M., et al. Deterioration of fracture healing in the mouse model of NF1 long bone dysplasia. Bone 2012, 51:651-660.
29. Elefteriou F., Kolanczyk M., Schindeler A., et al. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 2009, 149A:2327-2338.
30. El-Hoss J., Sullivan K., Cheng T., et al. A murine model of neurofibromatosis type 1 tibial pseudarthrosis featuring proliferative fibrous tissue and osteoclast-like cells. J Bone Miner Res 2012, 27:68-78.
31. Evans D.G., Baser M.E., McGaughran J., et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. J Med Genet 2002, 39:311-314.
32. Evans D.G., Howard E., Giblin C., et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A 2010, 152A:327-332.
33. Evans D.G., O'Hara C., Wilding A., et al. Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet 2011, 19:1187-1191.
34. Ferner R.E., Gutmann D.H. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res 2002, 62:1573-1577.
35. Ferner R.E., Golding J.F., Smith M., et al. [18 F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 2008, 19:390-394.
36. Fisher M.J., Loquidice M., Gutmann D.H., et al. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuo Oncol 2012, 14:790-797.
37. Friedman J.M., Birch P.H. Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 1997, 70:138-143.
38. Friedman J.M., Arbiser J., Epstein J.A., et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med 2002, 4:105-111.
39. Garg S., Lehtonen A., Huson S.M., et al. Autism and other psychiatric comorbidity in neurofibromatosis type 1: evidence from a population-based study. Dev Med Child Neurol 2013, 55:139-145.
40. Gill D.S., Hyman S.L., Steinberg A., et al. Age-related findings on MRI in neurofibromatosis type 1. Pediatr Radiol 2006, 36:1048-1056.
41. Gutmann D.H., Gurney J. Other malignancy. Neurofibromatosis: Phenotype, Natural History, and Pathogenesis 1999, 231-249. Johns Hopkins University Press, Baltimore. J.M. Friedman, D.H. Gutmann (Eds.).
42. Gutmann D.H., Cole J.L., Stone W.J., et al. Loss of neurofibromin in adrenal gland tumors from patients with neurofibromatosis type I. Genes Chromosomes Cancer 1994, 10:55-58.
43. Gutmann D.H., Aylsworth A., Carey J.C., et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and 2. JAMA 1997, 278:51.
44. Gutmann D.H., Rasmussen S.A., Wolkenstein P., et al. Gliomas presenting after age 10 in individuals with neurofibromatosis type 1 (NF1). Neurology 2002, 59:759-761.
45. Gutmann D.H., Blakeley J.O., Korf B.R., et al. Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs 2013, 22:443-462.
46. Habiby R., Silverman B., Listernick R., et al. Precocious puberty in children with neurofibromatosis type 1. J Pediatr 1995, 126:364.
47. Hegedus B., Banerjee D., Yeh T.H., et al. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Cancer Res 2008, 68:1520-1528.
48. Hsieh H.Y., Fung H.C., Wang C.J., et al. Epileptic seizures in neurofibromatosis type 1 are related to intracranial tumors but not to neurofibromatosis bright objects. Seizure 2011, 20:606-611.
49. Huijbregts S., Jahja R., De Sonneville L., et al. Social information processing in children and adolescents with neurofibromatosis type 1. Dev Med Child Neurol 2010, 52:620-625.
50. Huson S.M., Harper P.S., Compston D.A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988, 111:1355-1381.
51. Huson S.M., Compston D.A., Clark P., et al. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. 1. Prevalence, fitness, mutation rate, and effect of parental transmission of severity. J Med Genet 1989, 26:704-711.
52. Hyman S., Shores A., North K. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 2005, 65:1037-1044.
53. Hyman S.L., Arthur Shores E., North K.N. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Dev Med Child Neurol 2006, 48:973-977.
54. Isenberg J.C., Templer A., Gao F., et al. Attention skills in children with neurofibromatosis type 1. J Child Neurol 2013, 28:45-49.
55. Jessen W.J., Miller S.J., Jousma E., et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J Clin Invest 2013, 123:340-347.
56. Ji J., Shimony J., Gao F., et al. Optic nerve tortuosity in children with neurofibromatosis type 1. Pediatr Radiol 2013, 43:1336-1343.
57. Johnson K.J., Hussain I., Williams K., et al. Development of an international internet-based neurofibromatosis type 1 patient registry. Contemp Clin Trials 2013, 34:305-311.
58. Jouhilahti E.M., Peltonen S., Callens T., et al. The development of cutaneous neuofibromas. Am J Pathol 2011, 178:500-505.
59. Kimura N., Watanabe T., Fukase M., et al. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausen's disease. Mod Pathol 2002, 15:183-188.
60. King A.A., Debaun M.R., Riccardi V.M., et al. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000, 93:388-392.
61. King A., Listernick R., Charrow J., et al. Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 2003, 122A:95-99.
62. Korf B.R. Plexiform neurofibromas. Am J Med Genet 1999, 89:31-37.
63. Krab L.C., de Goede-Bolder A., Aarsen F.K., et al. Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial. JAMA 2008, 300:287-294.
64. Kulkantrakorn K., Geller T.J. Seizures in neurofibromatosis 1. Pediatr Neurol 1998, 19:347-350.
65. Kwon C.H., Zhao D., Chen J., et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 2008, 68:3286-3294.
66. Le D.T., Kong N., Zhu Y., et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004, 103:4243-4250.
67. Lehtonen A., Howie E., Trump D., et al. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol 2013, 55:111-125.
68. Levine S.M., Levine E., Taub P.J., et al. Electrosurgical excision technique for the treatment of multiple cutaneous lesions in neurofibromatosis type I. J Plast Reconstr Aesthet Surg 2008, 61:958-962.
69. Lewis R.A., Gerson L.P., Axelson K.A., et al. Von Recklinghausen NF1: incidence of optic gliomas. Ophthalmology 1984, 91:929.
70. Li W., Cui Y., Kushner S.A., et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 2005, 15:1961-1967.
71. Licis A.K., Vallorani A., Gao F., et al. Prevalence of sleep disturbances in children with neurofibromatosis type 1. J Child Neurol 2013, 28:1400-1405.
72. Lin A., Gutmann D.H. Advances in the treatment of neurofibromatosis-associated tumors. Nat Rev Clin Oncol 2013, 10:616-624.
73. Lisch K. Ueber Beteiligung der Augen, insbesondere das Vorkommen von Irisknotchen bei der Neurofibromatose (Recklinghausen). Z Augenheilkd 1937, 93:137-143.
74. Listernick R., Charrow J., Greenwald M.J., et al. Optic gliomas in children with neurofibromatosis type 1. J Pediatr 1989, 114:788-792.
75. Listernick R., Charrow J., Greenwald M., et al. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994, 125:63-66.
76. Listernick R., Darling C., Greenwald M., et al. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 1995, 127:718-722.
77. Listernick R., Louis D.N., Packer R.J., et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997, 41:143-149.
78. Listernick R., Ferner R.E., Liu G.T., et al. Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 2007, 61:189-198.
79. Matsui I., Tanimura M., Kobayashi N., et al. Neurofibromatosis type 1 and childhood cancer. Cancer 1993, 72:2746-2754.
80. Mautner V.F., Kluwe L., Thakker S.D., et al. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002, 44:164-170.
81. Mautner V., Brenner W., Fünsterer C., et al. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibroma in NF1. Anticancer Res 2007, 27:1819-1822.
82. Mautner V.F., Asuagbor F.A., Dombi E., et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol 2008, 10:593-598.
83. Mayes D.A., Rizvi T.A., Cancelas J.A., et al. Perinatal or adult Nf1 inactivation using tamoxifen-inducible PlpCre each cause neurofibroma formation. Cancer Res 2011, 71:4675-4685.
84. McGaughran J.M., Harris D.I., Donnai D., et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet 1999, 36:197-203.
85. Messiaen L.M., Callens T., Mortier G., et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000, 15:541-555.
86. Molloy P.T., Bilaniuk L.T., Vaughan S.N., et al. Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 1995, 45:1897-1902.
87. Moretti V.M., Crawford E.A., Staddon A.P., et al. Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol 2011, 34:417-421.
88. National Institutes of Health Consensus Development Conference Neurofibromatosis Conference Statement. Arch Neurol 1988, 45:575-578.
89. Nichols J.C., Amato J.E., Chung S.M. Characteristics of Lisch nodules in patients with neurofibromatosis type 1. J Pediatr Ophthalmol Strabismus 2003, 40:293-296.
90. North K.N., Riccardi V., Samango-Sprouse C., et al. Cognitive function and academic performance in neurofibromatosis 1: consensus statement from the NF1 Cognitive Disorders Task Force. Neurology 1997, 48:1121-1127.
91. Nunley K.S., Gao F., Albers A.C., et al. Predictive value of café au lait macules at initial consultation in the diagnosis of neurofibromatosis type 1. Arch Dermatol 2009, 145:883-887.
92. Ostendorf A.P., Gutmann D.H., Weisenberg J.L. Epilepsy in individuals with neurofibromatosis type 1. Epilepsia 2013, 54:1810-1814.
93. Petramala L., Giustini S., Zinnamosca L., et al. Bone mineral metabolism in patients with neurofibromatosis type 1 (von Recklingausen disease). Arch Dermatol Res 2012, 304:325-331.
94. Pollack I.F., Shultz B., Mulvihill J.J. The management of brainstem gliomas in patients with neurofibromatosis 1. Neurology 1996, 46:1652-1660.
95. Porter D.E., Prasad V., Foster L., et al. Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-associated tumours. Sarcoma 2009, 2009:756395.
96. Prada C.E., Rangwala F.A., Martin L.J., et al. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr 2012, 160:461-467.
97. Pride N.A., Payne J.M., North K.N. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 2012, 37:590-600.
98. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011, 11:761-774.
99. Rasmussen S.A., Friedman J.M. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151:33-40.
100. Rasmussen S.A., Yang Q., Friedman J.M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet 2001, 68:1110-1118.
101. Riccardi V. Von Recklinghausen neurofibromatosis. N Engl J Med 1981, 305:1617-1627.
102. Robertson K.A., Nalepa G., Yang F.C., et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012, 13:1218-1224.
103. Ruggieri M. Mosaic (segmental) neurofibromatosis type 1 (NF1) and type 2 (NF2): no longer neurofibromatosis type 5 (NF5). Am J Med Genet 2001, 101:178-180.
104. Salyer W.R., Salyer D.C. The vascular lesions of neurofibromatosis. Angiology 1974, 25:510-519.
105. Segal L., Darvish-Zargar M., Dilenge M.E., et al. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients. J AAPOS 2010, 14:155-158.
106. Sharif S., Ferner R., Birch J.M., et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006, 24:2570-2575.
107. Sharif S., Moran A., Huson S.M., et al. Women with neurofibromatosis 1 are at a moderately increased risk of developing breast cancer and should be considered for early screening. J Med Genet 2007, 44:481-484.
108. Shilyansky C., Lee Y.S., Silva A.J. Molecular and cellular mechanisms of learning disabilities: a focus on NF1. Annu Rev Neurosci 2010, 33:221-243.
109. Side L., Taylor B., Cayouette M., et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997, 336:1713-1720.
110. Side L.E., Emanuel P.D., Tyalor B., et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis type 1. Blood 1998, 92:267.
111. Silva A.J., Frankland P.W., Marowitz Z., et al. A mouse model for the learning and memory deficits associated with neurofibromatosis type I. Nat Genet 1997, 15:281-284.
112. Slater C., Hayes M., Saxe N., et al. Macromelanosomes in the early diagnosis of neurofibromatosis. Am J Dermatopathol 1986, 8:284-289.
113. Smith R. A Treatise on the Pathology, Diagnosis and Treatment of Neuroma 1849, Hodges and Smith, Dublin.
114. Soucy E.A., Gao F., Gutmann D.H., et al. Developmental delays in children with neurofibromatosis type 1. J Child Neurol 2012, 27:641-644.
115. Stevenson D.A., Moyer-Mileur L.J., Murray M., et al. Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 2007, 150:83-88.
116. Stiller C.A., Chessells J.M., Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994, 70:969-972.
117. Sung L., Anderson J.R., Arndt C., et al. Neurofibromatosis in children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004, 144:666-668.
118. Tischler A.S., Shih T.S., Williams B.O., et al. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr Pathol 1995, 6:323-335.
119. Tong J., Hannan F., Zhu Y., et al. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat Neurosci 2002, 5:95-96.
120. Ullrich N.J., Raja A.I., Irons M.B., et al. Brainstem lesions in neurofibromatosis type 1. Neurosurgery 2007, 61:762-767.
121. Valero M.C., Martín Y., Hernández-Imaz E., et al. A highly sensitive genetic protocol to detect NF1 mutations. J Mol Diagn 2011, 13:113-122.
122. van der Vaart T., Plasschaert E., Rietman A.B., et al. Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomized, placebo-controlled trial. Lancet Neurol 2013, 12:1076-1083.
123. Viskochil D., Buchberg A.M., Xu G., et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62:187.
124. Vlenterie M., Flucke U., Hofbauer L.C. Pheochromoctyoma and gastrointestinal stromal tumors in patients with neurofibromatosis type 1. Am J Med 2013, 126:174-180.
125. Vogel K.S., Klesse L.J., Velasco-Miguel S., et al. Mouse tumor model for neurofibromatosis type 1. Science 1999, 286:2176-2179.
126. Von Recklinghausen F. Über die multiplen Fibrome der Haut und ihre Beziehung zu den multiplen Neuromen 1882, Hirschwald, Berlin.
127. Waggoner D.J., Towbin J., Gottesman G., et al. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 2000, 92:132-135.
128. Wallace M.R., Marchuk D.A., Andersen L.B., et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990, 249:181.
129. Walsh K.S., Vélez J.I., Kardel P.G., et al. Symptomatology of autism spectrum disorder in a population with neurofibromatosis type 1. Dev Med Child Neurol 2013, 55:131-138.
130. Walther M.M., Herring J., Enquist E., et al. von Recklinghausen's disease and pheochromoctyomas. J Urol 1999, 162:1582-1586.
131. Wang W., Nyman J.S., Ono K., et al. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet 2011, 20:3910-3924.
132. Wessel L.E., Gao F., Gutmann D.H., et al. Longitudinal analysis of developmental delays in children with neurofibromatosis type 1. J Child Neurol 2013, 28:1689-1693.
133. Woodruff J.M. Pathology of tumors of the peripheral nerve sheath in type neurofibromatosis. Am J Med Genet 1999, 89:38.
134. Wu J., Williams J.P., Rizvi T.A., et al. Plexiform and dermal neurofibromas and pigmentation are caused by Nf1 loss in desert hedgehog-expressing cells. Cancer Cell 2008, 13:105-116.
135. Xu G.F., O'Connell P., Viskochil D., et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62:599-608.
136. Yang F.C., Ingram D.A., Chen S., et al. Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell 2008, 135:437-438.
137. Zanca A. Antique illustrations of NF1. Int J Dermatol 1980, 19:55.
138. Zhang W., Rhodes S.D., Zhao L., et al. Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone 2011, 48:1378-1387.
139. Zhu Y., Ghosh P., Charnay P., et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296:920-922.
140. Zhu Y., Guignard F., Zhao D., et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005, 8:119-130.
141. Zhu Y., Harada T., Liu L., et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development 2005, 132:5577-5588.